DXDISCOVERY INC
Reno, NV · Medtech · Private
Rapid point-of-care lateral flow immunoassay (LFIA) for detection of Bordetella pertussis antigen from nasopharyngeal specimens
dxdiscovery.com →- Grants
- $8.6M
- 17 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $4.1M
- 6 awards · Defense, Health and Human S
- #140 of 4531 in medtech
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Defense · SBIR 2014.1 Cbd Topic # 141-105 | $149,751 | |
| Federal grant | Department of Health and Human Services · Phase I · Point-of-care immunoassay for early diagnosis of pertussis | $297,775 | |
| Federal contract | Department of Defense · Igf::ot::igf | $999,822 | |
| Federal grant | Department of Health and Human Services · Phase I · Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum | $292,713 | |
| Federal contract | Department of Defense · Igf::ot::igf SBIR Proposal: H151-006-0012 | $149,715 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care immunoassay for early diagnosis of pertussis | $406,540 | |
| Federal grant | Department of Health and Human Services · Phase I · Point of care immunoassay for rapid diagnosis of tinea capitis | $199,920 | |
| Federal grant | Department of Health and Human Services · Phase I · Point of care immunoassay for rapid diagnosis of tinea capitis | $31,500 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care immunoassay for early diagnosis of pertussis | $351,332 | |
| Federal grant | Department of Health and Human Services · Phase I · Point of care immunoassay for rapid diagnosis of tinea capitis | $189,220 | |
| Federal contract· 1 of 2 same day | Department of Defense · R&d Effort-sbir Sequential Ph II Award Total Award Amount 999,995.10 | $997,495 | |
| Federal grant· 2 of 2 same day | Department of Defense · Phase II · High-affinity monoclonal antibodies that target Burkholderia Polysaccharide | $469,729 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care immunoassay for early diagnosis of pertussis | $289,172 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunoassay for early diagnosis of mucormycosis | $297,133 | |
| Federal grant | Department of Health and Human Services · Phase II · Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis | $588,922 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunoassay for early diagnosis of mucormycosis | $298,013 | |
| Federal contract | Department of Health and Human Services · Develop A Coccidioides-specific Antigen In Patient Serum Or Urine And Develop An Immunoassay For Coccidioides Galactomannan | $299,399 | |
| Federal grant | Department of Health and Human Services · Phase II · Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis | $893,413 | |
| Federal contract | Department of Health and Human Services · Develop Antigen Detection Immunoassay For Coccidiodes Galactomannan For Phase II | $1,469,691 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Point-of-care lateral flow immunoassay for diagnosis of pertussis | $1,009,408 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Point-of-care lateral flow immunoassay for diagnosis of pertussis | $1,009,408 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care lateral flow immunoassay for diagnosis of pertussis | $999,716 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care lateral flow immunoassay for diagnosis of pertussis | $989,461 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 137 | NOWDiagnostics, Inc. | $4.1M | $43M |
| 138 | SILK TECHNOLOGIES, LTD. | $4.1M | $5.0M |
| 139 | Neurable Inc. | $4.1M | $12M |
| 140 | DXDISCOVERY INC | $4.1M | — |
| 141 | SUVICA INC | $4.0M | — |
| 142 | IMMUNETICS, INC. | $4.0M | $1.5M |
| 143 | SWITCHBOX INC | $4.0M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Compositions For Pertussis Diagnosisapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.